Effect of Phytate (InsP6) and Other Inositol-Phosphates (InsP5, InsP4, InsP3, InsP2) on Crystallization of Calcium Oxalate, Brushite, and Hydroxyapatite

Biomolecules. 2023 Jun 29;13(7):1061. doi: 10.3390/biom13071061.

Abstract

Pathological calcifications may consist of calcium oxalate (CaOx), hydroxyapatite (HAP), and brushite (BRU). The objective of this study was to evaluate the effect of phytate (inositol hexakisphosphate, InsP6), InsP6 hydrolysates, and individual lower InsPs (InsP5, InsP4, InsP3, and InsP2) on the crystallization of CaOx, HAP and BRU in artificial urine. All of the lower InsPs seem to inhibit the crystallization of calcium salts in biological fluids, although our in vitro results showed that InsP6 and InsP5 were stronger inhibitors of CaOx crystallization, and InsP5 and InsP4 were stronger inhibitors of BRU crystallization. For the specific in vitro experimental conditions we examined, the InsPs had very weak effects on HAP crystallization, although it is likely that a different mechanism is responsible for HAP crystallization in vivo. For example, calciprotein particles seem to have an important role in the formation of cardiovascular calcifications in vivo. The experimental conditions that we examined partially reproduced the in vivo conditions of CaOx and BRU crystallization, but not the in vivo conditions of HAP crystallization.

Keywords: calcium oxalate; calcium phosphates; crystallization inhibitors; lower inositol phosphates; phytate; renal lithiasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium
  • Calcium Oxalate*
  • Crystallization
  • Durapatite / chemistry
  • Inositol 1,4,5-Trisphosphate
  • Phytic Acid*

Substances

  • inositol pentaphosphate
  • Phytic Acid
  • Calcium Oxalate
  • calcium phosphate, dibasic, dihydrate
  • Durapatite
  • Inositol 1,4,5-Trisphosphate
  • Calcium

Grants and funding

Grant PID2019-104331RB-I00 funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033.